Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report.
ALK
dysphagia
immune hyperprogression
lorlatinib
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
06
06
2023
accepted:
25
09
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Fusion of the anaplastic lymphoma kinase (ALK) gene is a rare driver in non-small cell lung cancer (NSCLC). Lorlatinib is a third-generation ALK inhibitor approved for the treatment of locally advanced or metastatic ALK
Identifiants
pubmed: 38020308
doi: 10.3892/ol.2023.14113
pii: OL-26-6-14113
pmc: PMC10644362
doi:
Types de publication
Case Reports
Langues
eng
Pagination
526Informations de copyright
Copyright: © Wang et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Respirol Case Rep. 2021 Jun 03;9(7):e00796
pubmed: 34123384
Thorac Cancer. 2020 May;11(5):1170-1179
pubmed: 32134200
J Clin Oncol. 2017 Aug 20;35(24):2781-2789
pubmed: 28609226
J Immunother Cancer. 2022 Apr;10(4):
pubmed: 35383114
Case Rep Oncol. 2019 Sep 25;12(3):728-736
pubmed: 31616281
Crit Rev Oncol Hematol. 2020 Jul;151:102969
pubmed: 32416346
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250
pubmed: 28351930
Lung Cancer. 2018 Nov;125:86-92
pubmed: 30429043
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
JTO Clin Res Rep. 2020 Apr 18;1(2):100044
pubmed: 34589934
J Clin Oncol. 2022 Nov 1;40(31):3593-3602
pubmed: 35605188
Target Oncol. 2020 Feb;15(1):55-65
pubmed: 32060867
Case Rep Oncol Med. 2016;2016:1075641
pubmed: 28116195
N Engl J Med. 2020 Nov 19;383(21):2018-2029
pubmed: 33207094
Int J Mol Sci. 2019 May 30;20(11):
pubmed: 31151303
Gynecol Oncol Rep. 2022 Jan 17;39:100923
pubmed: 35111894
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8
pubmed: 25733882
J Thorac Oncol. 2019 Nov;14(11):1901-1911
pubmed: 31446141
Lancet Oncol. 2018 Dec;19(12):1654-1667
pubmed: 30413378
J Med Chem. 2014 Jun 12;57(11):4720-44
pubmed: 24819116
Cancer Chemother Pharmacol. 2022 Jan;89(1):71-81
pubmed: 34698901